Program Overview

In 45 minutes, you can watch this on-demand activity based on the proceedings of the Transitions Into Clinical Practice for Retina Specialists CME course held on August 12, 2017, in Boston, Massachusetts. Learn about:

• The appropriate initial treatment of wet AMD, including selection of an anti-VEGF agent
• Updates in dry AMD, including the role of genetic testing, imaging and monitoring of disease progression, and emerging therapies to watch for
• Challenges in DME management, including initial treatment recommendations and selection of an anti-VEGF agent, and consideration of visual acuity gains versus retinal thickness/OCT results
• Challenges in DR management, including medical strategies to halt disease progression and initial treatment options 

Learning Objectives

After participating in this activity, learners should be better able to:

• Evaluate how results from clinical studies may influence management decisions for AMD, DME, and DR 
• Identify strategies for reducing patients’ risk of retinal disease progression

Faculty

Lisa C. Olmos de Koo, MD, MBA 
Associate Professor of Ophthalmology
Chief, Retina Division 
University of Washington
Seattle, WA

 

Faculty Biography

Lisa C. Olmos de Koo, MD, MBA

Lisa C. Olmos de Koo, MD, MBA, is Associate Professor of Ophthalmology and Chief of the Retina Division at the University of Washington, Seattle. Dr Olmos received her bachelor’s degree in chemistry cum laude from Harvard University, an MBA from Rice University, and her medical degree from Baylor College of Medicine in Houston, Texas, where she was the recipient of the American Medical Women’s Association scholastic achievement award. Dr Olmos completed her internship at Georgetown University in Washington, DC, and her ophthalmology residency and vitreoretinal fellowship at Bascom Palmer Eye Institute at the University of Miami. She was then selected to be Chief Resident and Co-Director of Ocular Trauma at Bascom Palmer.

Previously, Dr Olmos served as an Assistant Professor at the USC Roski Eye Institute, University of Southern California’s Keck School of Medicine in Los Angeles. During her time in Los Angeles, Dr Olmos was voted one of Pasadena’s “Top Doctors” from 2012 to 2016, and was the recipient of a “Rising Star” award from Los Angeles magazine in 2013. She was also the 2016 winner of the Vit-Buckle Society’s award for “Best Female Surgeon.” 

Dr Olmos’s research interests include artificial vision and retinal prostheses, novel therapies for macular degeneration and inherited retinal degenerations, treatment strategies for diabetic retinopathy, and retinal imaging modalities. She has a special interest in medical education and serves as the Retina Fellowship Program Director at the University of Washington. She is the current Co-Chair of the American Society of Retina Specialists’ Early Career section.

 

Faculty

Judy E. Kim, MD
Professor of Ophthalmology
Medical College of Wisconsin     
Milwaukee, WI

 

Faculty Biography

Judy E. Kim, MD

Judy E. Kim, MD, is Professor of Ophthalmology at the Medical College of Wisconsin in Milwaukee. She received her medical degree from The Johns Hopkins University School of Medicine in Baltimore, Maryland. She completed her ophthalmology residency at the Bascom Palmer Eye Institute of the University of Miami in Miami, Florida, followed by a vitreoretinal fellowship at the Medical College of Wisconsin. She is a former Howard Hughes-NIH research scholar.

Dr Kim has authored numerous publications, book chapters, and monographs about diabetic retinopathy, age-related macular degeneration, and other retinal diseases. She is a sought after lecturer both nationally and internationally. She is actively involved with a number of multicenter clinical trials, many as a site Principal Investigator, including those sponsored by the National Eye Institute (NEI), such as COMS, Age-Related Eye Disease Study 2, SCORE, and Diabetic Retinopathy Clinical Research Network (DRCRnet). She has been selected to serve as a DRCRnet Vice-Chair and a Planning Committee member for the National Eye Health Education Program of NEI. Her research interests include clinical trials, surgical retina, medicolegal claims, telemedicine, and ocular imaging. Her current research grants are in the areas of teleophthalmology, novel treatments for diabetic retinopathy, and imaging. 

 

Dr Kim has received numerous awards and honors, including being named in the “Best Doctors in America” annually since 2003 and is included in the US News & World Report Best Doctors list and Castle Connolly Top Doctors list. She has received an Achievement Award and Senior Achievement Award from the American Academy of Ophthalmology (AAO) as well as an Honor Award and Service Award from the American Society of Retina Specialists (ASRS). She is a Heed Foundation Fellow and has been selected to the Leadership Development Program of AAO. Dr Kim has also been elected to many regional and national leadership positions and serves on the editorial boards of a number of peer-reviewed journals, including JAMA Ophthalmology and OSLI Retina. She is a member of AAO, American Ophthalmological Society, Association for Research in Vision and Ophthalmology, ASRS, Macula Society, Retina Society, and Women in Retina, and serves on the committees of most of these organizations.

Disclosure Statements

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee who has no financial relationships with commercial interests.

Disclosures are as follows:

 

Faculty

Lisa C. Olmos de Koo, MD, MBA
Advisory/Medical Board: Alcon; ScienceBased Health 

Judy E. Kim, MD
Advisory/Medical Board: Genentech, Inc; Notal Vision 
Investigator: Notal Vision; Optos

Faculty Planning Committee

Consultant: Allergan, Inc; Bausch & Lomb Inc; Dutch Ophthalmic, USA; Santen Pharmaceutical Co

SriniVas R. Sadda, MD
Consultant: Allergan, Inc; Carl Zeiss Meditec, Inc; CenterVue, Inc; Genentech, Inc; Heidelberg Engineering, Inc; Iconic Therapeutics, Inc; Novartis; Optos; ThromboGenics

Gaurav K. Shah, MD
Speakers Bureau: Allergan, Inc; Johnson & Johnson; Regeneron Pharmaceuticals, Inc
Consultant: Allergan, Inc; Johnson & Johnson; Regeneron Pharmaceuticals, Inc

 

Independent Reviewer
Alex Yuan, MD, PhD 
Cole Eye Institute
Cleveland Clinic
Cleveland, Ohio
Nothing to disclose with regard to commercial support.

 

Educational Planning

Gordon Ringler
Nothing to disclose with regard to commercial support.
Spire Learning 
Jeanne Prater
Shareholder (spouse/partner): Johnson & Johnson
Employee (spouse/partner): Novo Nordisk
Jaime Symowicz, PhD
Nothing to disclose with regard to commercial support.
Lauren Waters
Nothing to disclose with regard to commercial support.

 

Disclaimer

The content and views presented in this educational activity are those of the presenters and do not necessarily reflect those of Dannemiller; Genentech, Inc; Regeneron Pharmaceuticals, Inc; or Spire Learning. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.

 

Off-label Statement 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

 

Levels of Evidence 

Level I includes evidence obtained from at least one properly conducted, well-designed, randomized controlled trial. It could include meta-analyses of randomized controlled trials. 

Level II includes evidence from the following: 

• Well-designed controlled trials without randomization
• Well-designed cohort or case-control analytic studies, preferably from more than one center
• Multiple time-series with or without intervention

Level III includes evidence obtained from one of the following: 

• Descriptive studies 
• Case reports
• Reports of expert committees/organizations (eg, PPP panel consensus with external peer review)

Source: American Academy of Ophthalmology Preferred Practice Patterns® (PPP) Guidelines